BI Asset Management Fondsmaeglerselskab A S Has $1.04 Million Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

BI Asset Management Fondsmaeglerselskab A S lifted its holdings in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 112.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,629 shares of the medical research company's stock after purchasing an additional 2,975 shares during the period. BI Asset Management Fondsmaeglerselskab A S's holdings in Charles River Laboratories International were worth $1,039,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Versant Capital Management Inc lifted its position in shares of Charles River Laboratories International by 1,071.4% in the 4th quarter. Versant Capital Management Inc now owns 164 shares of the medical research company's stock worth $30,000 after acquiring an additional 150 shares during the period. Pinnacle Bancorp Inc. grew its position in Charles River Laboratories International by 52.0% during the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock worth $35,000 after acquiring an additional 65 shares during the last quarter. GeoWealth Management LLC increased its stake in shares of Charles River Laboratories International by 311.5% in the fourth quarter. GeoWealth Management LLC now owns 251 shares of the medical research company's stock valued at $46,000 after buying an additional 190 shares in the last quarter. Pilgrim Partners Asia Pte Ltd bought a new position in shares of Charles River Laboratories International in the fourth quarter worth about $48,000. Finally, Tortoise Investment Management LLC lifted its holdings in Charles River Laboratories International by 77.7% during the 4th quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company's stock worth $49,000 after buying an additional 115 shares in the last quarter. Institutional investors own 98.91% of the company's stock.

Charles River Laboratories International Stock Performance

Shares of Charles River Laboratories International stock traded down $0.05 on Monday, hitting $114.62. The stock had a trading volume of 214,686 shares, compared to its average volume of 919,663. Charles River Laboratories International, Inc. has a twelve month low of $91.86 and a twelve month high of $254.15. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. The stock has a market cap of $5.63 billion, a price-to-earnings ratio of 763.53, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45. The business's 50 day moving average is $146.73 and its two-hundred day moving average is $170.98.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, beating the consensus estimate of $2.50 by $0.16. The firm had revenue of $1 billion during the quarter, compared to analysts' expectations of $983.63 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The company's quarterly revenue was down 1.1% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.46 EPS. Analysts forecast that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Insider Buying and Selling

In other news, CEO James C. Foster purchased 6,075 shares of the business's stock in a transaction dated Thursday, February 20th. The stock was bought at an average price of $165.01 per share, with a total value of $1,002,435.75. Following the acquisition, the chief executive officer now owns 183,639 shares in the company, valued at approximately $30,302,271.39. The trade was a 3.42 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, COO Birgit Girshick purchased 1,514 shares of Charles River Laboratories International stock in a transaction that occurred on Thursday, February 20th. The shares were purchased at an average price of $164.63 per share, for a total transaction of $249,249.82. Following the transaction, the chief operating officer now directly owns 55,058 shares in the company, valued at $9,064,198.54. This represents a 2.83 % increase in their position. The disclosure for this purchase can be found here. 1.30% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on CRL shares. The Goldman Sachs Group lowered shares of Charles River Laboratories International from a "buy" rating to a "neutral" rating and reduced their target price for the company from $190.00 to $170.00 in a research note on Friday, March 21st. Citigroup raised Charles River Laboratories International from a "sell" rating to a "neutral" rating and raised their price target for the stock from $155.00 to $175.00 in a research report on Tuesday, March 4th. Barclays cut their price objective on shares of Charles River Laboratories International from $160.00 to $145.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 10th. Morgan Stanley reduced their price target on Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating for the company in a research report on Wednesday, February 5th. Finally, William Blair downgraded Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a research report on Wednesday, January 22nd. One analyst has rated the stock with a sell rating and sixteen have assigned a hold rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $182.00.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).